review upsid quarter end-
sales/ep beat cc growth broad stabl demand
report sale vs street estimate constant
currenc growth vs conserv guid estimate fx
tailwind vs estimate opmargin broadli in-lin gm
off-set higher sg adj ep benefit sbc vs guid first
look overview result overal consist ytd result
solid quarter earn aid non-oper fx sbc tailwind
end-market show continu broad strength
result show see broad-bas strength across end-market
product group geographi key metric includ pharma cc
recur revenu cc china grow solid double-digit overal
consist recent commentari competitor belief end-market
strong divers sever year link year ahead
expect continu strength
guid organ growth in-lin ep messi tax
wat initi cc revenu guid msd expect look
margin commentari in-lin well howev ep guid came
bit lower expect due larg higher tax rate sbc
benefit turn headwind tax reform mechan also
anticip stronger buy-back benefit larg ou cash balanc
repatri management guid modest share repurchas target
off-set higher tax rate believ management bit conserv point
given ink hardli dri tax reform greater option
balanc sheet current guid indic includ possibl larger deal
tweak estim reiter neutral po
make chang estim chiefli tax rate fx revenu
vs prior adj ep
unchang vs prior maintain po
reiter neutral rate see limit upsid organ growth expect
await greater clariti capit deploy plan
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
corp lead supplier
analyt instrument consum
product use mainli research
qualiti assur applic pharmaceut
life scienc biochem industri academ
govern custom compani
posit liquid chromatographi market
busi posit
mass spectrometri market
posit thermal analysi market
look well posit continu
on-going momentum compani
product innov exposur appli
improv acquiti uplc instal
base grow howev compani face difficult
comparison may make difficult
share outperform near-term
po base dcf analysi assum wacc
termin growth impli pe multipl estim
slight premium peer believ multipl justifi given better
averag organ growth strong free cash flow higher slow
china weaker global economi slower expect uptak new product
slowdown pharma biotech spend downsid risk price object
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
